MX391779B - Variante de aav2 con aflibercept para usarse en el tratamiento de una condición o enfermedad ocular. - Google Patents
Variante de aav2 con aflibercept para usarse en el tratamiento de una condición o enfermedad ocular.Info
- Publication number
- MX391779B MX391779B MX2018015512A MX2018015512A MX391779B MX 391779 B MX391779 B MX 391779B MX 2018015512 A MX2018015512 A MX 2018015512A MX 2018015512 A MX2018015512 A MX 2018015512A MX 391779 B MX391779 B MX 391779B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- aflibercept
- disease
- eye condition
- aav2 variant
- Prior art date
Links
- 229960002833 aflibercept Drugs 0.000 title abstract 2
- 108010081667 aflibercept Proteins 0.000 title abstract 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas y métodos de las mismas para el tratamiento dedegeneración macular relacionada con la edad (DMRE) en un sujeto al administrar de manera intravítrea unacomposición farmacéutica adaptada para terapia génica, que comprende un vector que tiene una secuencia de ácido nucleico que codifica aflibercept.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351234P | 2016-06-16 | 2016-06-16 | |
| PCT/US2017/038003 WO2017218974A2 (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015512A MX2018015512A (es) | 2019-04-24 |
| MX391779B true MX391779B (es) | 2025-03-21 |
Family
ID=60663653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015512A MX391779B (es) | 2016-06-16 | 2017-06-16 | Variante de aav2 con aflibercept para usarse en el tratamiento de una condición o enfermedad ocular. |
| MX2022004786A MX2022004786A (es) | 2016-06-16 | 2018-12-13 | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004786A MX2022004786A (es) | 2016-06-16 | 2018-12-13 | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20190151409A1 (es) |
| EP (3) | EP3471780B1 (es) |
| JP (5) | JP6814822B2 (es) |
| KR (2) | KR102218265B1 (es) |
| CN (2) | CN109641065A (es) |
| AU (3) | AU2017286673B2 (es) |
| BR (1) | BR112018076124A2 (es) |
| CA (1) | CA3027737A1 (es) |
| CY (1) | CY1123697T1 (es) |
| DK (2) | DK3795181T3 (es) |
| ES (2) | ES2840059T3 (es) |
| FI (1) | FI3795181T3 (es) |
| HR (2) | HRP20251248T1 (es) |
| HU (1) | HUE051953T2 (es) |
| IL (3) | IL314568B2 (es) |
| LT (2) | LT3795181T (es) |
| MX (2) | MX391779B (es) |
| PL (1) | PL3795181T3 (es) |
| PT (2) | PT3471780T (es) |
| RS (2) | RS61311B1 (es) |
| SG (1) | SG11201811232XA (es) |
| SI (2) | SI3471780T1 (es) |
| SM (2) | SMT202500400T1 (es) |
| WO (1) | WO2017218974A2 (es) |
| ZA (1) | ZA201808538B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3042252T3 (en) | 2014-03-17 | 2025-11-19 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
| CN114480502A (zh) | 2015-03-02 | 2022-05-13 | 阿德夫拉姆生物技术股份有限公司 | 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法 |
| HUE051953T2 (hu) * | 2016-06-16 | 2021-04-28 | Adverum Biotechnologies Inc | Idõskori makula degeneráció kezelése AAV2 variáns és aflibercept alkalmazásával |
| AU2017345470B2 (en) | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| WO2018170473A1 (en) | 2017-03-17 | 2018-09-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| CN107661492A (zh) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | Vegf‑b的新用途 |
| CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
| CA3079565A1 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap |
| FI3717636T3 (fi) | 2017-11-27 | 2023-06-01 | 4D Molecular Therapeutics Inc | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä |
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| EP3773677B1 (en) * | 2018-04-12 | 2025-04-02 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Anti-aging compositions and methods of use |
| SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| AU2020231505A1 (en) * | 2019-03-04 | 2021-08-19 | Adverum Biotechnologies, Inc. | Sequential intravitreal administration of AAV gene therapy to contralateral eyes |
| WO2020219868A1 (en) * | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| KR20250051157A (ko) | 2019-06-05 | 2025-04-16 | 리제너론 파아마슈티컬스, 인크. | 정밀 투여량 전달을 위한 디바이스 및 방법 |
| CN114375195A (zh) * | 2019-09-11 | 2022-04-19 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法 |
| EP4028037A4 (en) * | 2019-09-11 | 2023-06-28 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| TWI819268B (zh) | 2020-01-16 | 2023-10-21 | 詹姆斯 Ｗ 希爾 | 藉由基因轉導改變眼睛顏色 |
| FR3111913A1 (fr) * | 2020-06-30 | 2021-12-31 | Eyevensys | Construction d’adn pour le traitement de pathologies oculaires |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| WO2022018516A1 (en) * | 2020-07-21 | 2022-01-27 | Inspirar Limited | Composition and method for treating eye diseases |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113817775B (zh) * | 2020-08-25 | 2023-02-17 | 南京吉迈生物技术有限公司 | 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用 |
| MX2023002695A (es) * | 2020-09-03 | 2023-05-19 | Univ Massachusetts | Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. |
| AU2021391433A1 (en) | 2020-12-01 | 2023-06-22 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| JP2021049374A (ja) * | 2020-12-09 | 2021-04-01 | 株式会社三洋物産 | 遊技機 |
| CA3215855A1 (en) * | 2021-04-27 | 2022-11-03 | Julie Clark | Methods of treating ocular diseases using aav2 variants encoding aflibercept |
| AU2023220237A1 (en) | 2022-02-21 | 2024-08-15 | Shanghai Regenelead Therapies Co., Ltd | Vegf-binding molecule and pharmaceutical use thereof |
| WO2025072688A2 (en) * | 2023-09-27 | 2025-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells |
| WO2025073297A1 (zh) * | 2023-10-06 | 2025-04-10 | 甘李药业股份有限公司 | 表达抗vegf融合蛋白的aav病毒载体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4005603T3 (da) * | 2011-04-22 | 2024-11-25 | Univ California | Adeno-associerede virus-virioner med variant kapsid og fremgangsmåder til anvendelse heraf |
| WO2013169614A1 (en) * | 2012-05-07 | 2013-11-14 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
| TWI702955B (zh) * | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ） |
| US20150111275A1 (en) * | 2012-06-11 | 2015-04-23 | Daniel V. Palanker | Optical regulation of gene expression in the retina |
| EA201690212A8 (ru) * | 2013-07-12 | 2016-08-31 | Офтотек Корпорейшн | Способы лечения или профилактики офтальмологических патологических состояний |
| CN105636986B (zh) * | 2013-10-18 | 2020-05-12 | 瑞泽恩制药公司 | 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物 |
| CN114480502A (zh) * | 2015-03-02 | 2022-05-13 | 阿德夫拉姆生物技术股份有限公司 | 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法 |
| HUE051953T2 (hu) * | 2016-06-16 | 2021-04-28 | Adverum Biotechnologies Inc | Idõskori makula degeneráció kezelése AAV2 variáns és aflibercept alkalmazásával |
-
2017
- 2017-06-16 HU HUE17814223A patent/HUE051953T2/hu unknown
- 2017-06-16 SM SM20250400T patent/SMT202500400T1/it unknown
- 2017-06-16 PL PL20196657.9T patent/PL3795181T3/pl unknown
- 2017-06-16 WO PCT/US2017/038003 patent/WO2017218974A2/en not_active Ceased
- 2017-06-16 FI FIEP20196657.9T patent/FI3795181T3/fi active
- 2017-06-16 KR KR1020197001023A patent/KR102218265B1/ko active Active
- 2017-06-16 SG SG11201811232XA patent/SG11201811232XA/en unknown
- 2017-06-16 EP EP17814223.8A patent/EP3471780B1/en active Active
- 2017-06-16 LT LTEP20196657.9T patent/LT3795181T/lt unknown
- 2017-06-16 MX MX2018015512A patent/MX391779B/es unknown
- 2017-06-16 EP EP25187377.4A patent/EP4671369A3/en active Pending
- 2017-06-16 SI SI201730553T patent/SI3471780T1/sl unknown
- 2017-06-16 IL IL314568A patent/IL314568B2/en unknown
- 2017-06-16 EP EP20196657.9A patent/EP3795181B1/en active Active
- 2017-06-16 DK DK20196657.9T patent/DK3795181T3/da active
- 2017-06-16 IL IL279919A patent/IL279919B2/en unknown
- 2017-06-16 BR BR112018076124A patent/BR112018076124A2/pt unknown
- 2017-06-16 RS RS20201517A patent/RS61311B1/sr unknown
- 2017-06-16 JP JP2018565845A patent/JP6814822B2/ja active Active
- 2017-06-16 RS RS20251055A patent/RS67328B1/sr unknown
- 2017-06-16 ES ES17814223T patent/ES2840059T3/es active Active
- 2017-06-16 PT PT178142238T patent/PT3471780T/pt unknown
- 2017-06-16 AU AU2017286673A patent/AU2017286673B2/en active Active
- 2017-06-16 HR HRP20251248TT patent/HRP20251248T1/hr unknown
- 2017-06-16 LT LTEP17814223.8T patent/LT3471780T/lt unknown
- 2017-06-16 PT PT201966579T patent/PT3795181T/pt unknown
- 2017-06-16 CA CA3027737A patent/CA3027737A1/en active Pending
- 2017-06-16 KR KR1020217004488A patent/KR20210021113A/ko not_active Ceased
- 2017-06-16 ES ES20196657T patent/ES3049818T3/es active Active
- 2017-06-16 DK DK17814223.8T patent/DK3471780T3/da active
- 2017-06-16 SI SI201731629T patent/SI3795181T1/sl unknown
- 2017-06-16 CN CN201780050283.2A patent/CN109641065A/zh active Pending
- 2017-06-16 HR HRP20201842TT patent/HRP20201842T1/hr unknown
- 2017-06-16 CN CN202311530329.4A patent/CN117531025A/zh active Pending
- 2017-06-16 SM SM20210010T patent/SMT202100010T1/it unknown
-
2018
- 2018-12-12 US US16/218,353 patent/US20190151409A1/en not_active Abandoned
- 2018-12-13 IL IL263686A patent/IL263686B/en active IP Right Grant
- 2018-12-13 MX MX2022004786A patent/MX2022004786A/es unknown
- 2018-12-18 ZA ZA2018/08538A patent/ZA201808538B/en unknown
-
2020
- 2020-09-16 JP JP2020155475A patent/JP2020203941A/ja not_active Withdrawn
- 2020-11-30 CY CY20201101133T patent/CY1123697T1/el unknown
-
2021
- 2021-09-01 AU AU2021225178A patent/AU2021225178B2/en active Active
- 2021-09-20 US US17/479,968 patent/US20220265740A1/en active Pending
-
2022
- 2022-07-15 JP JP2022113865A patent/JP2022137244A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095160A patent/JP2024113193A/ja active Pending
-
2025
- 2025-04-28 AU AU2025202930A patent/AU2025202930A1/en active Pending
- 2025-09-12 JP JP2025152535A patent/JP2025186377A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| CY1125152T1 (el) | Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου | |
| UY35195A (es) | Composiciones y metodos para proteinas de accion prolongada | |
| AR099837A1 (es) | Terapia génica para la retinitis pigmentaria | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| CL2018002825A1 (es) | Vacuna contra vrs | |
| DOP2018000245A (es) | Proteinas de fusion gdf15 y usos de estas | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| MX383887B (es) | Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich. | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| MX2017014532A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
| MX2017000143A (es) | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos. | |
| BR112019011462A2 (pt) | peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. | |
| BR112015030229A8 (pt) | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado | |
| EA201791907A1 (ru) | Бивалентная вакцина против вируса свиного гриппа | |
| BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
| CL2020002561A1 (es) | Composiciones y métodos para el tratamiento de la distrofia macular | |
| BR112018017240A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante? | |
| MX2021012783A (es) | Anticuerpos anti-pd-l1 modificados y metodos y usos para el tratamiento de una enfermedad neurodegenerativa. | |
| MX420767B (es) | Proteina de union al factor h modificada | |
| BR112018003580A2 (pt) | molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante | |
| MX381255B (es) | Vacunas contra el reovirus aviar. | |
| DOP2017000114A (es) | Composiciones farmacéuticas de acción prolongada para hepatitis c |